LinkMed logo
sp
sp divider
The LinkMed portfolio consists of a number of life science companies, several of which are nearing the commercialization phase, while others are already selling their products or services. Between them, these companies account for more than 50 different projects in a wide range of therapeutic areas – from HIV and cancer to eye disease and allergies.
COMPANIES IN SEVERAL SECTORS
LinkMed has created a portfolio of twelve companies, four in drug development and biotechnology and eight in diagnostics and medical technology
MANY COMPANIES, LOWER RISKS
By investing in several companies, we spread risks and reduce our exposure to the development in individual projects. Our goal is to continually develop and manage between 15 and 20 portfolio companies. Therefore, we plan to invest in several new companies in the coming years.
d

New opportunities with liver stem cells

Operations: NovaHep’s operations are focused the development of liver stem cell technology to treat liver disease and tests for liver toxicity and the metabolism of pharmaceutical compounds. The company also believes that it will be able to develop artificial livers, which can be used to alleviate the livers of patients with acute poisoning or patients waiting for a liver transplantation.

Sektor: Drug development and biotechnology

Therapeutic area: Liver stem cell therapy

CEO: Lars Martin

Chairman: Ingemar Lagerlöf

Venture manager: Lars Martin

Ownership stake: 49.5%

Address: NovaHep AB
Box 7710
Drottninggatan 33
SE-103 95 Stockholm

www.novahep.com

Back